TY - JOUR
T1 - Glioblastoma treatedwith magnetic resonance imaging-guided laser interstitial thermal therapy
T2 - safety, efficacy, and outcomes
AU - Kamath, Ashwin A.
AU - Friedman, Daniel D.
AU - Akbari, S. Hassan A.
AU - Kim, Albert H.
AU - Tao, Yu
AU - Luo, Jinqin
AU - Leuthardt, Eric C.
N1 - Publisher Copyright:
Copyright ©2018 by the Congress of Neurological Surgeons.
PY - 2019/4/1
Y1 - 2019/4/1
N2 - BACKGROUND: Despite the multitude of available treatments, glioblastoma (GBM) remains an aggressive and uniformly fatal tumor. Laser interstitial thermal therapy (LITT) is a novel, minimally invasive treatment that holds promise for treating patients with GBM who are not candidates for traditional open craniotomy. However, due to the recent introduction of LITT into clinical practice, large series that evaluate safety and long-term outcomes after LITT are lacking. OBJECTIVE: To present our institution's series of over 50 GBM patients treated with LITT, with regard to safety, efficacy, and outcomes. METHODS:We performed a retrospective descriptive study of patients with histologically proven GBM who underwent LITT. Data collected included demographics, tumor location and volume, tumor genetic markers, treatment volume, perioperative complications, and long-term follow-up data. RESULTS: We performed 58 LITT treatments for GBM in 54 patients over 5.5 yr. Fortyone were recurrent tumors while 17 were frontline treatments. Forty GBMs were lobar in location, while 18 were in deep structures (thalamus, insula, corpus callosum). Average tumor volume was 12.5 ± 13.4 cm3. Average percentage of tumor treated with the yellow thermal damage threshold (TDT) line (dose equivalent of 43?C for 2 min) was 93.3% ± 10.6%, and with the blue TDT line (dose equivalent of 43?C for 10 min) was 88.0% ± 14.2%. There were 7 perioperative complications (12%) and 2 mortalities (3.4%). Median overall survival after LITT for the total cohortwas 11.5mo, andmedian progressionfree survival 6.6 mo. CONCLUSION: LITT appears to be a safe and effective treatment for GBM in properly selected patients.
AB - BACKGROUND: Despite the multitude of available treatments, glioblastoma (GBM) remains an aggressive and uniformly fatal tumor. Laser interstitial thermal therapy (LITT) is a novel, minimally invasive treatment that holds promise for treating patients with GBM who are not candidates for traditional open craniotomy. However, due to the recent introduction of LITT into clinical practice, large series that evaluate safety and long-term outcomes after LITT are lacking. OBJECTIVE: To present our institution's series of over 50 GBM patients treated with LITT, with regard to safety, efficacy, and outcomes. METHODS:We performed a retrospective descriptive study of patients with histologically proven GBM who underwent LITT. Data collected included demographics, tumor location and volume, tumor genetic markers, treatment volume, perioperative complications, and long-term follow-up data. RESULTS: We performed 58 LITT treatments for GBM in 54 patients over 5.5 yr. Fortyone were recurrent tumors while 17 were frontline treatments. Forty GBMs were lobar in location, while 18 were in deep structures (thalamus, insula, corpus callosum). Average tumor volume was 12.5 ± 13.4 cm3. Average percentage of tumor treated with the yellow thermal damage threshold (TDT) line (dose equivalent of 43?C for 2 min) was 93.3% ± 10.6%, and with the blue TDT line (dose equivalent of 43?C for 10 min) was 88.0% ± 14.2%. There were 7 perioperative complications (12%) and 2 mortalities (3.4%). Median overall survival after LITT for the total cohortwas 11.5mo, andmedian progressionfree survival 6.6 mo. CONCLUSION: LITT appears to be a safe and effective treatment for GBM in properly selected patients.
KW - Brain tumors
KW - Gbm
KW - Glioblastoma
KW - Laser ablation
KW - Laser interstitial thermal therapy
KW - Litt
KW - Mri
KW - Thermoablation
UR - http://www.scopus.com/inward/record.url?scp=85062974459&partnerID=8YFLogxK
U2 - 10.1093/neuros/nyy375
DO - 10.1093/neuros/nyy375
M3 - Article
C2 - 30137606
AN - SCOPUS:85062974459
SN - 0148-396X
VL - 84
SP - 836
EP - 843
JO - Clinical Neurosurgery
JF - Clinical Neurosurgery
IS - 4
ER -